Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease
- 1 January 2020
- journal article
- letter
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 70, 20-22
Abstract
No abstract availableKeywords
Funding Information
- BIAL – PORTELA & Ca
- Biogen
- BIAL – PORTELA & Ca
- Michael J. Fox Foundation
- BIAL – PORTELA & Ca
- UCB Pharma
- BIAL – PORTELA & Ca
- Michael J. Fox Foundation
This publication has 6 references indexed in Scilit:
- Dysbiosis of gut microbiota in a selected population of Parkinson's patientsParkinsonism & Related Disorders, 2019
- Potential of Prebiotic Butyrogenic Fibers in Parkinson's DiseaseFrontiers in Neurology, 2019
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progressionEBioMedicine, 2019
- The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorderMovement Disorders, 2017
- Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiomeMovement Disorders, 2017
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controlsParkinsonism & Related Disorders, 2016